Why biotech sponsors want CRO data files with the PDF report

When a CRO sends a polished PDF report and nothing else, the sponsor still has a document, but not the data product that made it possible. Biotech teams ask for structured files alongside the report because they need to validate the result, combine it with other studies, reproduce the analysis, and carry the same numbers into safety, biomarker, and portfolio decisions without re-keying tables by hand.

A PDF is a human-readable endpoint, not a reusable asset. Once a study result has to support a submission, a diligence review, or a cross-study readout, the sponsor needs the dataset, the metadata, and the lineage that explain how the number was made.

The regulatory environment makes that need hard to ignore. According to the FDA study data submission guidance for CDER and CBER, most FDA-regulated clinical-study submissions require standardized electronic data, and nonconforming study data can lead FDA to refuse to file or receive an application. According to the FDA Study Data Technical Conformance Guide, each submitted data type requires its own definition file.

That need is not a one-time paperwork issue. According to the FDA Study Data Standards Resources, the agency updated its study-data technical guidance three times in 2024, which shows a living standards environment. The same FDA standards framework exists to give different systems a common structure, because clinical data arrives from multiple operational systems, vendors, and formats.

The PDF arrives late, after the important decisions have already started

The problem survives because the CRO contract is often written around a report, not around a reusable data package. If the statement of work asks for a final PDF, the CRO can meet the contract while the sponsor still lacks the structured outputs needed for submission, pooled analysis, pharmacovigilance, or partner diligence.

That mismatch usually does not show up until the sponsor is already deep into downstream work. Missing variables, unit conventions, code lists, and derivations are easier to ignore while the report is being reviewed than they are to reconstruct after database lock, when every correction has a cost and every delay hits a program milestone. The operational burden also lands unevenly across the sponsor team. Clinicians want to trust the table they see. Data managers want traceability back to source records. Statisticians want the exact analysis dataset, not a visually faithful reproduction of it. Regulatory operations want a package that can be assembled without reverse engineering a PDF.

The failure mode is structural, not cosmetic

A PDF hides the parts of the record that make data reusable. Tables can contain rounded values, merged cells, suppressed observations, pagination artifacts, and footnotes that matter to the meaning of the number but are easy to lose when the page is treated as the source. Figures are worse when the underlying observations are not available at all.

Structured delivery solves a different set of problems from a polished report. The sponsor can align subject identifiers, study visits, units, controlled terminology, and derivations across domains only when the files carry the same meaning in machine-readable form. Without that, the same clinical concept can show up under different names, different units, or different code systems across the laboratory file, the safety listing, and the final table.

Metadata is the other half of the problem. A dataset without versioned definitions, derivation logic, and relationships is hard to validate even when the numbers look plausible. The FDA asks for separate definition files for SDTM, ADaM, and SEND datasets because the values alone are not enough to make the package interpretable.

CROs are paid to finish the contracted deliverable, and a report is easier to scope than a continuing data product. Structured delivery brings validation, documentation, change control, and sometimes support after lock. If the sponsor does not specify acceptance criteria for machine-readable data, it should not be surprised when the vendor optimizes for the simpler handoff.

Structured delivery changes the sponsor's options, not just the workflow

The strongest case for structured results delivery is that it makes the data usable after the report has been read. A sponsor that receives structured files can validate the CRO's numbers against source outputs, combine the study with prior or parallel work, and feed the same record into safety review, biomarker analysis, and portfolio decisions without manual transcription. That shifts the sponsor's job from recovering meaning to governing it.

A reference design usually starts with a canonical model on the sponsor side, with incoming CRO outputs mapped into consistent subject, study, and domain structures. Around that sits a metadata layer, a rules engine for conformance checks, a review queue for exceptions, and an audit log that records what changed and why.

Done well, the result is a controlled path from source transfers to reviewable datasets to the final report. The report stays important, but it becomes one view of governed data rather than the only place where the truth exists.

Where historical studies arrive as PDF-only packages, document extraction can help with remediation. Table extraction, optical character recognition, layout parsing, and terminology matching can create candidate structured records for human review, but they cannot recover numbers that were rounded away, aggregated, or never shown in the first place. That makes extraction a triage tool for legacy work, not a substitute for asking CROs for the files up front.

For teams that want a place to start, a useful first step is to compare the report, the statistical output, and the delivered files against one another before the next lock. A practical checklist belongs in the contract, and QueryNow has a free paper that is worth reading before that discussion: The mid-market AI advantage.

For preclinical and translational groups, the same logic applies across assay transfers, imaging outputs, and specialty data. The differences are in the file types and the validation rules, not in the underlying need for traceable results. Teams focused on that operating model can look at AI agents for preclinical CROs or the broader Pharma & Life Sciences AI work.

The cost is not zero. Structured delivery requires sponsors to define the canonical model, enforce metadata standards, and hold vendors to the same acceptance criteria across every study. It also requires patience when legacy files do not line up cleanly, because the first reconciliation effort usually reveals that the real problem was not the PDF. It was the absence of a data contract.

The decision in front of biotech sponsors now is whether to accept the PDF as the finish line and keep paying for manual reconciliation later, or require data files, metadata, and validation evidence as part of the original handoff so the result can be used again without being rebuilt.

QueryNow builds the foundation enterprise AI runs on, and the agents that run on it. Talk to our team about the workflow you want to start with: every engagement starts with one scoped workflow and acceptance criteria agreed in writing before the build starts. Talk to our team.

Sources

• Study Data for Submission to CDER and CBER, 2024-09-08
• Study Data Technical Conformance Guide, 2026-11-04
• Study Data Standards Resources | FDA, 2026-09-29